CN Mobile Logo

Search form



The Role of Intralesional Therapies in Melanoma

Sanjiv S. Agarwala, MD
Through the emergence of new immunotherapies, treatment of melanoma is undergoing a long-awaited revolution. Ongoing research will clarify the outlines of the place that intralesional therapies will occupy in the therapeutic armamentarium in the years ahead.


Waiting as long as 3 months from a melanoma diagnosis to sentinel lymph node biopsy had no effect on 5-year survival or sentinel node positivity rate, according to the results of a study.

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.

Ironically, the patients who can benefit the most from CLND in terms of regional nodal basin disease control are the patients who are least likely to experience a survival benefit.

A large percentage of patients with metastatic melanoma in Europe may not have access to innovative medicines used to treat the disease, according to the results of a survey.

Melanoma patients diagnosed prior to age 18 had a higher survival vs adult patients, despite having similar tumor depth and more frequent nodal metastases.

Lack of knowledge and a belief that dark skin protects against skin cancer are among the barriers preventing minority, uninsured, and immigrant populations from adopting methods for skin cancer prevention.

The use of sunscreen with an SPF of 15 or greater was associated with about a 30% reduction in the risk for melanoma among a group of Norwegian women.


Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.